Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

LQDA vs ZBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LQDA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

LQDA Overall Winner 6-Pillar Tally: LQDA 5 – 1 ZBIO Matrix Metrics: LQDA 7 – 3 ZBIO

As of Nov 16, 2026, Liquidia Corporation (LQDA) is the stronger overall head-to-head candidate over Zenas BioPharma, Inc. (ZBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LQDA carries a Unified Composite Score of 25.6/100 (SELL) at $56.37 (16.4x Forward P/E, 47.1% operating margin), whereas ZBIO carries 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin).

  • Composite vs. Pillar Nuance: While ZBIO currently prints a higher short-term Unified Composite Score (49.4/100 HOLD vs. LQDA 25.6/100 SELL), LQDA captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (47.1% vs. -2747.5% operating margin) and revenue trajectory (+314.6% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: LQDA is currently in a Breakdown options structure phase (RSI 64.4); meanwhile ZBIO is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LQDA vs ZBIO
LQDA NASDAQ Head-to-Head Winner
Liquidia Corporation Common Stock
Pharmaceutical Preparations
$56.37
-1.81% 1D
Market Cap $5.2B
TTM Revenue $622M
Forward P/E 16.4x
Beta / 30D Vol 0.99β · 77% Vol
Unified Composite Score
25.6 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 64
RSI-14: 64.4 · SMA20: $46.46 · SMA50: $48.72
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.16β · 59% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -5.2%) with fading momentum, RSI 49
RSI-14: 49.0 · SMA20: $27.99 · SMA50: $28.48

6-Pillar Scorecard Institutional Category Breakdown (LQDA 5 – 1 ZBIO)

Columns: Metric · LQDA · ZBIO
1. Valuation Multiples LQDA
Forward P/E 16.4x N/M
Trailing P/E 13.8x N/M
PEG Ratio N/M N/M
EV / Revenue 8.0x N/M
2. Growth & Scale LQDA
Revenue Growth (YoY) +314.6% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $622M $11M
Market Cap $5.2B $1.9B
3. Profitability & Quality LQDA
Gross Margin 92.7% N/A
Operating Margin 47.1% -2747.5%
Net Profit Margin -15.2% 0.0%
Return on Equity (ROE) 131.8% -265.1%
4. Balance Sheet & Cash Flow LQDA
Cash Generation (TTM) $288M -$273M
Cash Flow Margin 46.3% N/A
Net Cash / Leverage $227M Net Cash $177M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ZBIO
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 69.3% (10th %ile) 103.9% (13th %ile)
Put/Call OI Skew 0.08x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat LQDA
OpEx & R&D Intensity 45.6% of Rev ($284M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LQDA (7) vs ZBIO (3)
Institutional Metric LQDA ZBIO Criterion Row Edge
Market Capitalization
Scale
$5.2B $1.9B Larger Scale LQDA
Trailing P/E Ratio
Valuation
13.8x N/M Lower Multiple LQDA
Forward P/E Ratio
Valuation
16.4x N/M Lower Multiple LQDA
Revenue Growth (YoY)
Growth
+314.6% -100.0% Higher Growth LQDA
Operating Margin (TTM)
Profitability
47.1% -2747.5% Higher Margin LQDA
Net Profit Margin
Profitability
-15.2% 0.0% Higher Margin ZBIO
Return on Equity (ROE)
Capital Efficiency
131.8% -265.1% Higher ROE LQDA
52-Week Range Position
Momentum
48% ($22–$94) 46% ($14–$45) Stronger Trend LQDA
Beta / 30D Volatility
Risk Regime
0.99β · 77% Vol 1.16β · 59% Vol Lower Realized Risk ZBIO
Unified Institutional Score
Composite Signal
25.6 / 100 (SELL) 49.4 / 100 (HOLD) Higher Composite ZBIO
Trailing 12M Revenue (USD)
Operating Scale
$622M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
92.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 8.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$288M ($227M Net Cash) -$273M ($177M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LQDA +51.66 pp
LQDA: +64.1% · ZBIO: +12.44%
3M Horizon ZBIO +11.69 pp
LQDA: -24.16% · ZBIO: -12.47%
6M Horizon ZBIO +66.22 pp
LQDA: -1.05% · ZBIO: +65.17%
1Y Horizon LQDA +130.92 pp
LQDA: +109.24% · ZBIO: -21.68%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LQDA Revenue ZBIO Revenue LQDA Op. Margin ZBIO Op. Margin Margin Leader
FY2019 $10M N/A -580.1% N/A LQDA
FY2020 $0M N/A -7989.0% N/A LQDA
FY2021 $10M N/A -263.0% N/A LQDA
FY2022 $20M N/A -243.3% N/A LQDA
FY2023 $20M $50M -419.6% -74.3% ZBIO
FY2024 $10M $10M -866.6% -3277.8% LQDA
FY2025 $160M $10M -32.5% -3830.6% LQDA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LQDA BREAKDOWN
81d in phase · OBV ACCUMULATION
Current IV 69.3%
IV Percentile 10th %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact LQDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ZBIO CONSOLIDATION
58d in phase · OBV ACCUMULATION
Current IV 103.9%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ZBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LQDA Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $5.2B market capitalization and 47.1% operating margin.
OpEx & R&D Reinvestment 45.6% of Rev ($284M)
90D Engineering Disclosures 0 Published
ZBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and -2747.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LQDA vs ZBIO Key Questions & Quantitative Answers

As of Nov 16, 2026, Liquidia Corporation (LQDA) is the stronger overall head-to-head candidate over Zenas BioPharma, Inc. (ZBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LQDA carries a Unified Composite Score of 25.6/100 (SELL) at $56.37 (16.4x Forward P/E, 47.1% operating margin), whereas ZBIO carries 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin). Composite vs. Pillar Nuance: While ZBIO currently prints a higher short-term Unified Composite Score (49.4/100 HOLD vs. LQDA 25.6/100 SELL), LQDA captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (47.1% vs. -2747.5% operating margin) and revenue trajectory (+314.6% vs. -100.0% YoY). Technical & Structure Timing Caution: LQDA is currently in a Breakdown options structure phase (RSI 64.4); meanwhile ZBIO is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LQDA leads the Growth & Scale pillar: LQDA posts +314.6% YoY revenue growth and +0.0% YoY earnings growth on $622M TTM revenue (92.7% gross margin, 47.1% operating margin), compared with ZBIO at -100.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -2747.5% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), LQDA cumulative revenue shifted +1500.0% while ZBIO shifted -80.0%. In operating R&D and SG&A reinvestment, LQDA deploys 45.6% of Rev ($284M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ZBIO.

LQDA screens cheaper on headline valuation multiples. LQDA trades at 16.4x Forward P/E, 13.8x Trailing P/E, N/M PEG, and 8.0x EV/Revenue (46.3% FCF margin), whereas ZBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LQDA (131.8% ROE) versus ZBIO (-265.1% ROE) capital efficiency.

In options market volatility and institutional positioning, LQDA carries 69.3% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.99β · 77% Vol realized risk). By comparison, ZBIO carries 103.9% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.16β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.